Prediction of treatment benefit and predictor importance
exacerbations
REGRESSION, ASTHMA
The predicted severe exacerbation rate was 0.71/year lower in the treatment versus the placebo group with 365 days of treatment (average annual rate of exacerbation: 1.13/year in the mepolizumab group vs. 1.84/year in the control group). The predicted difference in ACQ5 score over 365 days was 0.22 lower in the in the treatment versus the placebo group (average ACQ5 score: 1.40 in the exposure group vs. 1.62 in the control group) (The model calibration results are reported in 
Importance of individual standardized covariates for predicting the reduction of severe exacerbations and the 5-item Asthma Control Questionnaire (ACQ5) score with 1-year mepolizumab treatment. Left panel, reduction in rate of severe exacerbations in 365 days of follow up. Right panel, reduction in ACQ5 scores in 365 days of follow up. The x-axis shows the absolute value of the regression coefficient for each covariate. BMI, body mass index, FEV